We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Impact of Implantable Cardioverter-Defibrillator Therapy on a Secondary Prevention Population

Ankit Rathod, MD1; Apurva Badheka, MD2; Abhishek Deshmukh, MD3
[+] Author Affiliations
1Department of Cardiology, Cedars Sinai Medical Center, Los Angeles, California
2Department of Cardiology, University of Miami, Miami, Florida
3Department of Cardiology, University of Arkansas for Medical Sciences, Little Rock
JAMA Intern Med. 2013;173(22):2093-2094. doi:10.1001/jamainternmed.2013.10402.
Text Size: A A A
Published online


To the Editor We read with great interest the recent article by Borne et al.1 The researchers should be congratulated for having provided a detailed review on implantable cardioverter-defibrillator (ICD) therapies and their effects on health outcomes and strategies to reduce these therapies. The adverse prognostic value of ICD therapies (shocks and antitachycardia pacing) in a primary prevention population has been well proven in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). However the implications of ICD shocks in a secondary prevention population is unclear.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





December 9, 2013
Ryan T. Borne, MD; Paul D. Varosy, MD; Frederick A. Masoudi, MD, MSPH
1Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
1Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado2VA Eastern Colorado Healthcare System, Denver
JAMA Intern Med. 2013;173(22):2094. doi:10.1001/jamainternmed.2013.10385.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...